Analyst Ratings For Agios Pharmaceuticals Inc (NASDAQ:AGIO)
Today, Piper Jaffray Companies set its price target on Agios Pharmaceuticals Inc (NASDAQ:AGIO) to $125.00 per share.
There are 9 Buy Ratings, 3 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Agios Pharmaceuticals Inc (NASDAQ:AGIO) is Buy with a consensus target price of $97.50 per share, a potential 14.75% upside.
Some recent analyst ratings include
- 7/23/2018-SunTrust Banks Reiterated Rating of Buy.
- 7/20/2018-Cann Reiterated Rating of Hold.
- 5/23/2018-Citigroup initiated coverage with a Buy rating.
Recent Insider Trading Activity For Agios Pharmaceuticals Inc (NASDAQ:AGIO)
Agios Pharmaceuticals Inc (NASDAQ:AGIO) has insider ownership of 3.02% and institutional ownership of 95.11%.
- On 7/25/2018 Steven L Hoerter, Insider, sold 2,050 with an average share price of $84.58 per share and the total transaction amounting to $173,389.00.
- On 7/9/2018 Carman Alenson, Insider, sold 272 with an average share price of $84.94 per share and the total transaction amounting to $23,103.68.
- On 7/5/2018 Scott Biller, Insider, sold 3,000 with an average share price of $83.50 per share and the total transaction amounting to $250,500.00.
- On 6/22/2018 Steven L Hoerter, Insider, sold 2,050 with an average share price of $97.58 per share and the total transaction amounting to $200,039.00.
- On 6/14/2018 Kaye I Foster-Cheek, Director, sold 9,000 with an average share price of $93.55 per share and the total transaction amounting to $841,950.00.
- On 6/12/2018 Christopher Bowden, Insider, sold 2,000 with an average share price of $92.89 per share and the total transaction amounting to $185,780.00.
- On 6/5/2018 Scott Biller, Insider, sold 3,000 with an average share price of $93.37 per share and the total transaction amounting to $280,110.00.
About Agios Pharmaceuticals Inc (NASDAQ:AGIO)
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML. The company also develops Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase I clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase I clinical trial for advanced solid tumors; Phase III clinical trials for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination and Phase III clinical trials for newly diagnosed AML patients. In addition, it is developing AG-881, a pan-IDH mutant inhibitor that is in Phase I clinical trial for the treatment of hematologic malignancies; and AG-348, a small molecule potent activator that is in Phase II clinical trials for the treatment of pyruvate kinase deficiency. Agios Pharmaceuticals has a collaboration and license agreement with Celgene Corporation to discover, develop, and commercialize disease-altering therapies in oncology; and Celgene International II Sarl to develop and commercialize AG-881 products. The company was founded in 2007 and is based in Cambridge, Massachusetts.
Recent Trading Activity for Agios Pharmaceuticals Inc (NASDAQ:AGIO)
Shares of Agios Pharmaceuticals Inc closed the previous trading session at 84,80 −1,93 2,22 % with 89.5 shares trading hands.